Rapid Readouts: Results from the Phase 3 VISION Study

Video

A. Oliver Sartor, MD, presents data from the American Society of Clinical Oncology 2021 annual meeting from the VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

A. Oliver Sartor, MD, discusses data from the following presentation:

  • Phase 3 study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION) (Morris, ASCO 2021, LBA4)
    • The objective of this study is to report results from the phase 3 VISION study (NCT03511664) of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC).
    • 177Lu-PSMA-617 is a targeted radioligand therapy that delivers β-particle radiation to mCRPC lesions that highly express prostate-specific membrane antigen (PSMA).
    • Men with PSMA-positive mCRPC previously treated with androgen receptor pathway inhibitors and 1 to 2 taxane regimens were randomly assigned 2:1 to either 177Lu-PSMA-617 (7.4 GBq every 6 weeks x 4 to 6 cycles) plus standard of care (SOC) vs SOC alone (investigator determined but excluded cytotoxic chemotherapy and radium-223).
    • Alternate primary end points were radiographic progression-free survival (rPFS) using Prostate Cancer Clinical Trials Working Group 3 criteria by independent central review, and overall survival (OS).
    • Key secondary end points were objective response rate (ORR; RECIST v1.1), disease control rate (DCR), and time to first symptomatic skeletal event (SSE).
    • Conclusions: efficacy
      • 177Lu-PSMA-617 plus SOC significantly improved median rPFS vs SOC alone (median rPFS, 8.7 vs 3.4 months; HR, 0.40 [99.2% CI, 0.29-0.57]; P < .001, one-sided) in the rPFS analysis set (n=581).
      • Median OS was also significantly improved versus SOC alone (median OS, 15.3 vs 11.3 months; HR, 0.62 [95% CI, 0.52-0.74]; P < .001, one-sided) in the OS analysis set (n=831).
      • Key secondary end points were statistically significant between the treatment arms in favor of 177Lu-PSMA-617 plus SOC, including ORR (29.8% vs 1.7%), DCR (89.0% vs 66.7%), and time to first SSE (median time, 11.5 vs 6.8 months; HR, 0.50).
    • Conclusions: safety
      • A higher rate of high-grade treatment-emergent adverse events was observed with 177Lu-PSMA-617 (52.7% vs 38.0).
      • Fatigue, bone marrow suppression, dry mouth, and nausea and vomiting were the highest all grade and grade 3-5 treatment-emergent adverse events in both study arms.
  • 177Lu-PSMA-617 plus SOC is a well-tolerated regimen that improves rPFS and prolongs OS compared with SOC alone in men with PSMA-positive mCRPC.
Related Videos
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD
Daniel Spratt, MD
Daniel Spratt, MD
Philip J. Koo, MD
Anthony D'Amico MD, PhD
Mary Ellen Taplin, MD
Emmanuel Antonarakis, MD
Mary-Ellen Taplin, MD